Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Buisson

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2024
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter studyM Hupé, A Streichenberger, P Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodiesM Collins, J M Michot, F X Danlos, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2018
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experienceP Wils, Y Bouhnik, P Michetti, et al.
Journal of Crohn'S & Colitis|February 23, 2019
Adalimumab for patients with Crohn's disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort studyG Pineton de Chambrun, B Pariente, P Seksik, et al.
The American Journal of Gastroenterology|August 28, 2025
Sub-cutaneous infliximab for perianal Crohn's disease: the BioLap-Rem multicentre study from the GETAIDM André, J Kirchgesner, D Laharie, et al.
Journal of Crohn'S & Colitis|December 14, 2020
Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAIDA Buisson, J Filippi, A Amiot, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 9, 2024
Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide studyS Bendaoud, S Nahon, L Beaugerie, et al.
Alimentary Pharmacology & Therapeutics|June 9, 2017
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort studyA Amiot, M Serrero, L Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|December 19, 2017
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohortS Tadbiri, L Peyrin-Biroulet, M Serrero, et al.
ESMO Open|September 15, 2023
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across EuropeP Hofman, F Calabrese, I Kern, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2024
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter studyM Hupé, A Streichenberger, P Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodiesM Collins, J M Michot, F X Danlos, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2018
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experienceP Wils, Y Bouhnik, P Michetti, et al.
Journal of Crohn'S & Colitis|February 23, 2019
Adalimumab for patients with Crohn's disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort studyG Pineton de Chambrun, B Pariente, P Seksik, et al.
The American Journal of Gastroenterology|August 28, 2025
Sub-cutaneous infliximab for perianal Crohn's disease: the BioLap-Rem multicentre study from the GETAIDM André, J Kirchgesner, D Laharie, et al.
Journal of Crohn'S & Colitis|December 14, 2020
Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAIDA Buisson, J Filippi, A Amiot, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 9, 2024
Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide studyS Bendaoud, S Nahon, L Beaugerie, et al.
Alimentary Pharmacology & Therapeutics|June 9, 2017
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort studyA Amiot, M Serrero, L Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|December 19, 2017
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohortS Tadbiri, L Peyrin-Biroulet, M Serrero, et al.
ESMO Open|September 15, 2023
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across EuropeP Hofman, F Calabrese, I Kern, et al.
Pageof 5